JY
PRLD icon

Jeff Yass’s Prelude Therapeutics PRLD Stock Holding History

Jeff Yass’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$592K Buy
111,000
+90,000
+429% +$392K ﹤0.01% 9514
2026
Q1 		$71.8K Buy
+21,000
New +$55.1K ﹤0.01% 12497
2022
Q4 		– Sell
-81,000
Closed -$535K – 13403
2022
Q3 		$535K Sell
81,000
-25,500
-24% -$172K ﹤0.01% 8304
2022
Q2 		$556K Buy
106,500
+66,500
+166% +$338K ﹤0.01% 8010
2022
Q1 		$276K Buy
+40,000
New +$366K ﹤0.01% 10474

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Jeff Yass's PRLD Position: Q2 2026 in Review

Jeff Yass sold out of Prelude Therapeutics (PRLD) in Q2 2026, closing a stake of 267,788 shares — an estimated $1.17M sold.

Jeff Yass first reported a position in PRLD in Q2 2021 and held it in 12 quarters. The position peaked at $916K in Q1 2026. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Jeff Yass reported no remaining Prelude Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 267,788 Prelude Therapeutics shares in Q2 2026, an estimated $1.17M.
  • Jeff Yass first reported a position in Prelude Therapeutics in Q2 2021 and held it in 12 quarters.
  • Jeff Yass's Prelude Therapeutics position peaked at $916K in Q1 2026.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.